Scholarlink

Background <p>Triple-negative breast cancer is an aggressive and its diverse subtype that lacks targeted treatment options and often shows resistance to immune-based therapies. This study aimed to identify immune-related regulatory axes within BLIA and MLIA subtypes by integrating ceRNA network of ncRNAs and mRNAs, and to evaluate HMGB3 as a potential therapeutic target.</p> Methods <p>Transcriptomic datasets from GEO and TCGA were analyzed to identify DE-mRNAs. Network analysis was performed using STRING, CytoHubba, CytoNCA, and MCODE in Cytoscape. HMGB3-associated ncRNAs were examined for functional relevance. Molecular docking, ADMET evaluation, and molecular dynamics (MD) simulations were conducted to assess ligand binding and complex stability.</p> Results <p>HMGB3 showed strong association with poor prognosis in MLIA subtype. The HMGB3–miR-214-3p–let-7f-5p–NEAT1 axis emerged as a potential immune-modulatory pathway. Docking revealed high affinity for Pimicotinib (− 8.0&#xa0;kcal/mol), CID17584963 (7.0&#xa0;kcal/mol), and CID1763476 (kcal/mol). MD simulations confirmed the stability of these complexes, reflected by lower RMSD, reduced residue fluctuations, compact conformations, and decreased solvent exposure.</p> Conclusion <p>This work identifies HMGB3 as a promising immunotherapeutic target in the MLIA subtype of TNBC and highlights Pimicotinib, CID17584963, and CID1763476 as potential HMGB3 inhibitors for drug repurposing strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrative bioinformatics and molecular simulations identify HMGB3 as a key immune modulator in triple negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Uma Chaudhary,
  • Mythili Asaithambi

摘要

Background

Triple-negative breast cancer is an aggressive and its diverse subtype that lacks targeted treatment options and often shows resistance to immune-based therapies. This study aimed to identify immune-related regulatory axes within BLIA and MLIA subtypes by integrating ceRNA network of ncRNAs and mRNAs, and to evaluate HMGB3 as a potential therapeutic target.

Methods

Transcriptomic datasets from GEO and TCGA were analyzed to identify DE-mRNAs. Network analysis was performed using STRING, CytoHubba, CytoNCA, and MCODE in Cytoscape. HMGB3-associated ncRNAs were examined for functional relevance. Molecular docking, ADMET evaluation, and molecular dynamics (MD) simulations were conducted to assess ligand binding and complex stability.

Results

HMGB3 showed strong association with poor prognosis in MLIA subtype. The HMGB3–miR-214-3p–let-7f-5p–NEAT1 axis emerged as a potential immune-modulatory pathway. Docking revealed high affinity for Pimicotinib (− 8.0 kcal/mol), CID17584963 (7.0 kcal/mol), and CID1763476 (kcal/mol). MD simulations confirmed the stability of these complexes, reflected by lower RMSD, reduced residue fluctuations, compact conformations, and decreased solvent exposure.

Conclusion

This work identifies HMGB3 as a promising immunotherapeutic target in the MLIA subtype of TNBC and highlights Pimicotinib, CID17584963, and CID1763476 as potential HMGB3 inhibitors for drug repurposing strategies.